These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 20831363)

  • 1. Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity.
    Uckun FM; Qazi S
    Expert Opin Ther Pat; 2010 Nov; 20(11):1457-70. PubMed ID: 20831363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton's tyrosine kinase as a drug discovery target.
    Pan Z
    Drug News Perspect; 2008 Sep; 21(7):357-62. PubMed ID: 19259548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical potential of targeting Bruton's tyrosine kinase.
    Uckun FM
    Int Rev Immunol; 2008; 27(1-2):43-69. PubMed ID: 18300055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).
    Feng Y; Duan W; Cu X; Liang C; Xin M
    Expert Opin Ther Pat; 2019 Apr; 29(4):217-241. PubMed ID: 30888232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bruton's tyrosine kinase prevents activation of the anti-apoptotic transcription factor STAT3 and promotes apoptosis in neoplastic B-cells and B-cell precursors exposed to oxidative stress.
    Uckun F; Ozer Z; Vassilev A
    Br J Haematol; 2007 Feb; 136(4):574-89. PubMed ID: 17367410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent patents in the discovery of small molecule inhibitors of JAK3.
    Wilson LJ
    Expert Opin Ther Pat; 2010 May; 20(5):609-23. PubMed ID: 20402545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
    Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G
    Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy.
    Liu L; Di Paolo J; Barbosa J; Rong H; Reif K; Wong H
    J Pharmacol Exp Ther; 2011 Jul; 338(1):154-63. PubMed ID: 21521773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.
    Seiler T; Dreyling M
    Expert Opin Investig Drugs; 2017 Aug; 26(8):909-915. PubMed ID: 28661188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase.
    Uckun FM; Zheng Y; Cetkovic-Cvrlje M; Vassilev A; Lisowski E; Waurzyniak B; Chen H; Carpenter R; Chen CL
    Clin Cancer Res; 2002 May; 8(5):1224-33. PubMed ID: 12006542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
    Liang C; Tian D; Ren X; Ding S; Jia M; Xin M; Thareja S
    Eur J Med Chem; 2018 May; 151():315-326. PubMed ID: 29631132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tec family kinases in inflammation and disease.
    Horwood NJ; Urbaniak AM; Danks L
    Int Rev Immunol; 2012 Apr; 31(2):87-103. PubMed ID: 22449071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's tyrosine kinase as a new therapeutic target.
    Uckun FM; Tibbles HE; Vassilev AO
    Anticancer Agents Med Chem; 2007 Nov; 7(6):624-32. PubMed ID: 18045057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Bruton's tyrosine kinase inhibitors currently in development.
    D'Cruz OJ; Uckun FM
    Onco Targets Ther; 2013; 6():161-76. PubMed ID: 23493945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inducible tyrosine kinase inhibitors: a review of the patent literature (2010 - 2013).
    Norman P
    Expert Opin Ther Pat; 2014 Sep; 24(9):979-91. PubMed ID: 24990480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.
    Shi Q; Tebben A; Dyckman AJ; Li H; Liu C; Lin J; Spergel S; Burke JR; McIntyre KW; Olini GC; Strnad J; Surti N; Muckelbauer JK; Chang C; An Y; Cheng L; Ruan Q; Leftheris K; Carter PH; Tino J; De Lucca GV
    Bioorg Med Chem Lett; 2014 May; 24(9):2206-11. PubMed ID: 24685542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. QSAR analysis of nicotinamidic compounds and design of potential Bruton's tyrosine kinase (Btk) inhibitors.
    Santos-Garcia L; Assis LC; Silva DR; Ramalho TC; da Cunha EF
    J Biomol Struct Dyn; 2016 Jul; 34(7):1421-40. PubMed ID: 26305710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Itk inhibitors: a patent review.
    Lo HY
    Expert Opin Ther Pat; 2010 Apr; 20(4):459-69. PubMed ID: 20218931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bruton's tyrosine kinase inhibitors: lessons learned from bench-to-bedside (first) studies.
    Ysebaert L; Michallet AS
    Curr Opin Oncol; 2014 Sep; 26(5):463-8. PubMed ID: 25033375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective.
    Brullo C; Villa C; Tasso B; Russo E; Spallarossa A
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.